Stock INSM INSMED INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Company Insmed Incorporated

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
25.66 USD +0.25% Intraday chart for Insmed Incorporated +2.95% -17.22%
04-23 Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases MT
04-11 Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating MT

Business Summary

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Number of employees: 912

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapies
100.0 %
245 100.0 % 305 100.0 % +24.39%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
73.5 %
186 75.8 % 224 73.5 % +20.54%
Japan
21.5 %
57 23.0 % 66 21.5 % +16.33%
Europe and Rest of World
5.0 %
3 1.2 % 15 5.0 % +434.64%

Managers

Managers TitleAgeSince
Will Lewis CEO
 Chief Executive Officer 55 09/09/12
Sara Bonstein DFI
 Director of Finance/CFO 43 30/01/20
Martina Flammer CTO
 Chief Tech/Sci/R&D Officer 60 18/12/19
Roger Adsett COO
 Chief Operating Officer 55 26/09/16
Walter R. Perkins CTO
 Chief Tech/Sci/R&D Officer - 30/11/10
Eleanor Barisser IRC
 Investor Relations Contact - -
Michael Smith LAW
 General Counsel 47 31/03/14
Eugene Jeffrey Sullivan PRN
 Corporate Officer/Principal 59 28/02/15
Drayton Wise PRN
 Corporate Officer/Principal 49 31/01/14
S. Schaeffer HRO
 Human Resources Officer 55 30/09/12

Members of the board

Members of the board TitleAgeSince
Carol Schafer BRD
 Director/Board Member 60 31/03/20
Al Altomari BRD
 Director/Board Member 65 01/08/12
Melvin Sharoky BRD
 Director/Board Member 73 30/04/01
David McGirr BRD
 Director/Board Member 69 29/10/13
David Brennan BRD
 Director/Board Member 70 28/05/14
Will Lewis CEO
 Chief Executive Officer 55 09/09/12
Clarissa Desjardins BRD
 Director/Board Member 57 31/10/19
Elizabeth Anderson BRD
 Director/Board Member 66 07/11/18
Yao Lee BRD
 Director/Board Member 54 16/05/18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 148,555,217 146,937,967 ( 98.91 %) 0 98.91 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.513 %
14,125,521 9.513 % 383 M $
BlackRock Advisors LLC
7.336 %
10,892,985 7.336 % 296 M $
T. Rowe Price International Ltd.
7.249 %
10,763,771 7.249 % 292 M $
STATE STREET CORPORATION
3.993 %
5,929,933 3.993 % 161 M $
T. Rowe Price Investment Management, Inc.
3.940 %
5,850,606 3.940 % 159 M $
Palo Alto Investors LP
3.712 %
5,511,721 3.712 % 150 M $
Deep Track Capital LP
3.603 %
5,350,000 3.603 % 145 M $
Fidelity Management & Research Co. LLC
3.429 %
5,091,614 3.429 % 138 M $
Macquarie Investment Management Business Trust
3.132 %
4,651,492 3.132 % 126 M $
William Blair Investment Management LLC
2.867 %
4,256,687 2.867 % 115 M $

Company contact information

Insmed, Inc.

700 US Highway 202/206

08807-3365, Bridgewater

+908 977 9900

http://www.insmed.com
address Insmed Incorporated(INSM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Insmed Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
25.59 USD
Average target price
44.12 USD
Spread / Average Target
+72.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INSMED INCORPORATED Stock Insmed Incorporated
-17.22% 3.8B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-12.60% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. INSM Stock
  4. Company Insmed Incorporated